Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab for eosinophilic granulomatosis with polyangiitis
2012-004385-17Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA), sponsored by GSK. Started Oct 2013; status: completed.
02
Drugs
mepolizumab
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on 2012-004385-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004385-17.